Tag: Corcept Therapeutics

December 13, 2018

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

Corcept Therapeutics (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow...
November 19, 2018

Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and...
August 10, 2018

Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and...
May 9, 2018

Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and...
March 16, 2018

Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and...
February 23, 2018

Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and...
May 4, 2017

Corcept To Show New Treatments of Hypercortisolism

Corcept Therapeutics announced it will host a presentation at the American Association of Clinical Endocrinologists meeting.